Australia TGA approves psilocybin and MDMA for use in treating depression and PTSD
Feb. 06, 2023.
1 min. read Interactions
Revolutionizing Therapy: UBC Professor Develops AI-Powered Questionnaire for Mental Health Assessment
The Therapeutic Goods Administration (TGA), Australia’s esteemed medical regulatory body, has made a ground-breaking declaration: it has granted approval for the utilization of psychedelics, such as MDMA and psilocybin, in treating mental health conditions. Commencing from July 1st, authorized psychiatrists can now prescribe MDMA for patients suffering from PTSD, while psilocybin can be recommended for those with treatment-resistant depression – but only under the strictest of medical supervision.
Although studies have generated optimistic outcomes, indicating that psychedelics could be a viable option for treating depression and PTSD, there’s still much that needs to be explored and understood about the long-term effects of these drugs. The TGA, in its ruling, has emphasized that psychedelics will only be obtainable in controlled medical environments, and all other uses will continue to be strictly prohibited. The decision to allow the use of psychedelics as a therapeutic intervention was taken as a last resort, for individuals grappling with treatment-resistant mental illnesses, but experts caution that more research is indispensable before a widespread implementation of these drugs can be approved.
Interesting story? Please click on the 👍 button below!